{"analyses":[{"ciLowerLimit":"-2.132","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-1.038","groupDescription":"From an ANCOVA model including scores at Baseline, treatment group, region and MRI/CRP classification.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","paramType":"Difference","paramValue":"-1.585","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.30","value":"-1.44"},{"groupId":"OG001","spread":"0.24","value":"-3.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"The BASFI is a validated disease-specific instrument for assessing physical function. The BASFI comprises 10 items relating to the past week. The BASFI is the mean of the 10 scores such that the total score ranges from 0 (Easy) to 10 (Impossible), with lower scores indicating better physical function. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.","dispersionType":"Standard Error","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Full Analysis Set (FAS).","id":"OG000","title":"Placebo (FAS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the FAS.","id":"OG001","title":"CZP 200 mg Q2W (FAS)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The FAS consisted of all subjects in the RS who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"From Baseline to Week 52","title":"Change From Baseline to Week 52 in the Bath Ankylosing Spondylitis Functional Index (BASFI)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}